Johnson & Johnson (NYSE:JNJ) Shares Steady at High Levels Even After 5.5% Earnings Revision
Johnson & Johnson closed Friday at $259.24, marking its highest finish since July 29. Shares remain 5.7% under the 52-week high of $274.90.
Dow edges unchanged as software drop offset by index structure
The Dow Jones Industrial Average finished nearly flat in Wednesday's U.S. cash session, closing just shy of 52,219 after peaking at 52,511.21.
S&P 500 finishes at 7,533.77; chip downturn overshadows broad earnings gains
The S&P 500 ended Thursday at 7,533.77, slipping 0.51% even as almost 75% of its components rose. The Nasdaq Composite dropped 1.47%.
Johnson & Johnson leans on two main drugs for almost all Q2 sales growth
Johnson & Johnson mostly leaned on Tremfya and Darzalex for almost all of its Q2 sales growth, according to a review of results from the healthcare group. This leaves investors asking how much depth backs up J&J’s higher 2026 guidance.
The Biggest Earnings Reports This Week: Banks, TSMC and Netflix Put Wall Street’s Profit Boom on Trial
The market’s central question is whether the profit surge can broaden beyond artificial-intelligence chips and energy without exposing weaker credit. The evidence points to a cautious yes: analysts expect S&P 500 second-quarter earnings to rise 23.4% from a year earlier, and this week’s bank slate will test loan demand and consumer health. The answer still hinges on Taiwan Semiconductor Manufacturing Co. defending its high-growth, heavy-investment outlook. Guidance — management’s forecast for coming quarters — matters more now than another round of backward-looking beats.
Healthcare Stocks: J&J, UnitedHealth, Abbott Face Test on Sector’s 9% Earnings Drop
NEW YORK, July 12, 2026, 4:33 p.m. EDT — Healthcare stocks head into the week with Johnson & Johnson, UnitedHealth and Abbott set to gauge whether the sector’s reported 9% earnings decline is showing up in results.
Johnson & Johnson (NYSE:JNJ) finishes above analyst target after Dow shift
Johnson & Johnson climbed $9.06, or 3.57%, to finish at $263.04 Thursday. That's about $21.8 billion added to its market cap based on 2.41 billion shares, according to WSJ. Shares also hit $263.10, matching the stock's 52-week high. Volume came in at 7.9 million, just below the 65-day average.
Amazon takes number one spot on 2026 Fortune 500; regional shifts seen
Amazon has taken the No. 1 spot on the 2026 Fortune 500, Fortune said, unseating Walmart after 13 years at the top. The change put Amazon ahead for the first time in more than a decade and drove shifts in regional tallies for Pennsylvania, New Jersey and New England. Fortune’s 72nd annual list put the collective revenue at $21.0 trillion, with profits at $2.1 trillion and a workforce of 30.5 million worldwide.
3 Dividend Stocks for the Long Haul in 2026
Defensive dividend stocks joined Friday’s rally as the S&P 500 rose 0.5% and the Dow finished up 0.7%. Johnson & Johnson traded at $240.87, Coca-Cola at $82.62, and Procter & Gamble at $149.61 at the close, Friday figures show. J&J’s P/E ratio is around 27.9, Coca-Cola’s 26.0, and P&G’s 21.9.
Johnson & Johnson Shares Hold Up in Market Selloff — Looking at What May Shift JNJ Next Week
Johnson & Johnson heads into the week with less clutter than much of the Street. Shares gained 2.0% to $232.77 on Friday, while most stocks sank. The last regular session wrapped up at 4:00 p.m. New York time on June 5. With markets closed Saturday, that $232.77 is the number investors see.
Johnson & Johnson stock trades higher ahead of Memorial Day: Eyes on next moves for JNJ
Johnson & Johnson shares gained 1.13% on Friday, closing at $234.34, and ended the week up about 3.4%. That put the Dow name ahead of the S&P 500’s weekly move going into the U.S. Memorial Day holiday.
Kenvue Stock Watch Just Got Fresh Signals Before Monday — Here’s Why KVUE Traders Are Paying Attention
Stock Traders Daily published a new AI-generated trading note on Kenvue Inc. on Sunday, setting fresh price levels for the Tylenol maker before U.S. shares reopen on Monday. The note put KVUE in a neutral near-term and mid-term setup, while calling its longer-term signal weak, against a current-price marker of $17.11.
Johnson & Johnson Shares Drop Friday, Week Ahead in Focus
Johnson & Johnson stock starts the week above Friday’s lows. The drug and medical-device company fell 1.77% to $226.71 on Friday as markets dropped, but the shares ended last week with a gain.
Dow Jones Today: Why The Dow Is Holding Up While Nasdaq Sinks On AI Worries
The Dow Jones Industrial Average managed a modest gain Tuesday, bucking declines in the S&P 500 and a steeper slide for the Nasdaq as traders moved out of AI stocks and into more stable blue chips. According to LSEG figures cited by Reuters, the Dow closed up 100.62 points, or 0.20%, at 49,268.41. The S&P 500 slipped 0.64%, with the Nasdaq down 1.24%.
Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump
Johnson & Johnson topped Wall Street’s Q1 expectations on Tuesday, helped by surging sales from the cancer therapy Darzalex and the psoriasis drug Tremfya. Those gains made up for a sharp decline in Stelara, which used to be a major driver. Revenue climbed 9.9% to $24.1 billion, beating forecasts of $23.6 billion. Adjusted earnings reached $2.70 a share, also above the $2.66 consensus. The company lifted its 2026 outlook.
Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod
Johnson & Johnson on Tuesday said it’s filed with the European Medicines Agency to expand Tecvayli’s EU label, aiming to allow the therapy as a single agent for adults with relapsed or refractory multiple myeloma who’ve already had at least one prior treatment. That would move the drug up in the treatment sequence for the blood cancer, where, according to the company, patients still encounter some of the toughest care gaps.
Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next
Johnson & Johnson slipped roughly 0.7% Wednesday, even as the company announced its lupus drug candidate nipocalimab received Fast Track designation from the U.S. FDA. Shares traded at $245.07, down $1.68 in the afternoon session.
Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling
Shares of Arcellx surged roughly 78% to $113.92 Monday morning, following news that Gilead Sciences will acquire the cancer therapy maker—pushing the stock close to the buyout price. The takeover puts Arcellx’s valuation as high as $7.8 billion, factoring in a contingent sales-related bonus.
Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears
Johnson & Johnson shares closed down 1.8% on Friday at $242.49, leaving the JNJ stock price softer into the weekend.
Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data
Johnson & Johnson is weighing a sale of its DePuy Synthes orthopedics division that could fetch more than $20 billion, according to a source familiar with the situation, speaking to Reuters on Thursday. The company hasn’t commented yet. This potential sale marks a pivot from J&J’s previously outlined plan to spin off DePuy Synthes over the next 18 to 24 months. CFO Joe Wolk previously indicated no major updates would come before mid-2026. DePuy pulled in $9.3 billion in sales for 2025 and has faced thousands of hip implant lawsuits, Reuters noted.
TechStock² Updates
